Oragenics Receives European Union CPNP Notifications for ProBiora3® Cosmetic Tablets
Oragenics,
Inc. (OTCQB: OGEN) (OTCBB: OGEN), today announced its ProBiora3®
tablets intended to freshen breath, whiten teeth and contribute to
overall oral health has successfully completed an independent third
party review of its Cosmetic Product Safety Report. ProBiora3® is
Oragenics’ proprietary blend of probiotics specifically designed for
oral care, and is now formulated as a cosmetic mouthwash tablet for use
in the European Union. All Oragenics’ independent distributors can now
distribute the ProBiora3® tablets in the EU under a Cosmetic designation.
“This cosmetic indication is the first phase in expanding our sales and
marketing efforts with our current European partners and will make our
ProBiora3®product line even more attractive to additional partnerships.
We believe Europeans understand and appreciate the value and health
benefits of probiotics,” stated Dr. John N. Bonfiglio, President and
CEO, Oragenics, Inc. “We will continue to enhance our European
regulatory status as clinical data from our ongoing trials become
available.”
About Oragenics, Inc.
Oragenics, Inc. is focused on becoming the world leader in novel
antibiotics against infectious disease and probiotics for oral health
for humans and pets. Oragenics, Inc. has established an exclusive
worldwide channel collaboration for lantibiotics, a novel class of broad
spectrum antibiotics, with Intrexon Corporation Inc., a synthetic
biology company. The collaboration will allow Oragenics access to
Intrexon's proprietary technologies with the idea of accelerating the
development of much needed new antibiotics that will work against
resistant strains of bacteria. Oragenics also develops, markets and
sells proprietary probiotics specifically designed to enhance oral
health for humans and pets, under the brand names Evora
and ProBiora3®
in over 13 countries worldwide.
For more information about Oragenics, visit www.oragenics.com.
Follow Oragenics on Facebook
and Twitter.
Safe Harbor Statement: Under the Private Securities
Litigation Reform Act of 1995: This release includes forward-looking
statements that reflect the Company’s current views with respect to
future events and financial performance. These forward-looking
statements are based on management’s beliefs and assumptions and
information currently available. The words “believe,” “expect,”
“anticipate,” “intend,” “estimate,” “project” and similar expressions
that do not relate solely to historical matters identify forward-looking
statements. Investors should be cautious in relying on forward-looking
statements because they are subject to a variety of risks,
uncertainties, and other factors that could cause actual results to
differ materially from those expressed in any such forward-looking
statements. These factors include, but are not limited to our ability to
raise additional capital to sustain our operations beyond June 30, 2012
and those set forth in our most recently filed annual report on Form
10-K and quarterly report on Form 10-Q, and other factors detailed from
time to time in filings with the U.S. Securities and Exchange
Commission. We expressly disclaim any responsibility to update
forward-looking statements.
